Nimotuzumab

CAS No. 828933-51-3

Nimotuzumab( —— )

Catalog No. M28966 CAS No. 828933-51-3

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1017 In Stock
10MG 1359 In Stock
25MG 2024 In Stock
50MG 2688 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nimotuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
  • Description
    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    828933-51-3
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-1400.
molnova catalog
related products
  • Lifirafenib

    Lifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.

  • Dacomitinib hydrate

    Dacomitinib hydrate is a highly selective and second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor family of tyrosine kinases.

  • AZD-9291 mesylate

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.